Benitec Biopharma Inc. (BNTC)

USD 11.84

(-7.28%)

Market Cap (In USD)

274.88 Million

Revenue (In USD)

216 Thousand

Net Income (In USD)

-21.75 Million

Avg. Volume

23.35 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.69-13.29
PE
-
EPS
-
Beta Value
0.879
ISIN
US08205P2092
CUSIP
08205P100
CIK
1808898
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jerel A. Banks M.D., Ph.D.
Employee Count
-
Website
https://benitec.com
Ipo Date
2014-06-24
Details
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.